[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338274-105":59,"doc-detail-338274-en":122},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":115,"head_meta":117,"extra_data":119,"updated_unix":121},105,"en","molecular-targets-and-strategies-in-the-development-of-nucleic-acid-cancer-vaccines-from-shared-to-personalized-antigens","Molecular targets and strategies in the development of nucleic acid cancer vaccines - from shared to personalized antigens","","Recent breakthroughs in cancer immunotherapies highlight the value of mobilizing the immune system against tumors. Cancer vaccines are increasingly viewed as tools to target neoantigens rather than only to induce protective immunity. Extensive preclinical work and many clinical trials have advanced neoantigen discovery and vaccine formulation, supporting personalized approaches. DNA and mRNA platforms are emerging as particularly promising, relying on sequencing, antigen prediction, and tailored manufacturing pipelines while considering technical and clinical constraints.",{"@graph":69,"@context":114},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-targets-and-strategies-in-the-development-of-nucleic-acid-cancer-vaccines-from-shared-to-personalized-antigens/338274/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-targets-and-strategies-in-the-development-of-nucleic-acid-cancer-vaccines-from-shared-to-personalized-antigens/338274.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108],{"name":109,"@type":110,"acceptedAnswer":111},"How do cancer vaccines relate to immune checkpoint inhibitors (ICIs)?","Question",{"text":112,"@type":113},"Neoantigen vaccines can be used together with ICIs, which block proteins that suppress CD8 T cell cytotoxicity, and ICIs have shown strong performance in cancers with high mutational burden.","Answer","https://schema.org",{"og:url":83,"og:type":116,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":118,"canonical":83},"index,follow",{"doc_id":120,"site_id":62},338274,1790193305,{"code":4,"msg":5,"data":123},{"doc_id":120,"user_id":124,"nickname":92,"user_avatar":125,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":131,"language":132,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":67,"update_tm":136,"read_time":137,"preview_page_count":19,"preview_urls":138},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Chi et al.  \nJournal of Biomedical Science (2024) 31:94 [https://doi.org/10.1186/s12929-024-01082-x](https://doi.org/10.1186/s12929-024-01082-x)  \nREVIEW Open Access  \nMolecular targets and strategies  \nin the development of nucleic acid cancer vaccines: from shared to personalized antigens  \nWei‑Yu Chi 1†, Yingying Hu2†, Hsin‑Che Huang2†, Hui‑Hsuan Kuo3†, Shu‑Hong Lin4,5†, Chun‑Tien Jimmy Kuo6†, Julia Tao7, Darrell Fan7, Yi‑Min Huang7, Annie A. Wu7, Chien‑Fu Hung7,8,9 and T.‑C. Wu7,8,9,10*  \nAbstract  \nRecent breakthroughs in cancer immunotherapies have emphasized the importance of harnessing the immune sys‑ tem for treating cancer. Vaccines, which have traditionally been used to promote protective immunity against patho‑ gens, are now being explored as a method to target cancer neoantigens. Over the past few years, extensive preclinical research and more than a hundred clinical trials have been dedicated to investigating various approaches to neoan‑ tigen discovery and vaccine formulations, encouraging development of personalized medicine. Nucleic acids (DNA and mRNA) have become particularly promising platform for the development of these cancer immunotherapies. This shift towards nucleic acid‑based personalized vaccines has been facilitated by advancements in molecular techniques for identifying neoantigens, antigen prediction methodologies, and the development of new vaccine platforms. Generating these personalized vaccines involves a comprehensive pipeline that includes sequencing of patient tumor samples, data analysis for antigen prediction, and tailored vaccine manufacturing. In this review, we will discuss the various shared and personalized antigens used for cancer vaccine development and introduce strategies for iden‑ tifying neoantigens through the characterization of gene mutation, transcription, translation and post translational modifications associated with oncogenesis. In addition, we will focus on the most up‑to‑date nucleic acid vaccine platforms, discuss the limitations of cancer vaccines as well as provide potential solutions, and raise key clinical and technical considerations in vaccine development.  \nKeywords Cancer vaccine, Tumor antigens, Neoantigens, DNA, mRNA, Clinical trial  \n†Wei‑Yu Chi, Yingying Hu, Hsin‑Che Huang, Hui‑Hsuan Kuo, Shu‑Hong Lin, and Chun‑Tien Jimmy Kuo have contributed equally to this work.  \n*Correspondence: T.‑C. Wu [wutc@jhmi.edu](wutc@jhmi.edu)  \n1 Physiology, Biophysics and Systems Biology Graduate Program, Weill Cornell Medicine, New York, NY, USA  \n2 Tri‑Institutional PhD Program in Chemical Biology, Memorial Sloan Kettering Cancer Center, New York, NY, USA  \n3 Pharmacology PhD Program, Weill Cornell Medicine, New York, NY, USA  \n4 Department of Epidemiology, The University ofTexas MD Anderson Cancer Center, Houston, TX, USA  \n5 The University of Texas Graduate School of Biomedical Sciences at Houston and MD Anderson Cancer Center, Houston, TX, USA  \n6 Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, USA  \n7 Department of Pathology, Johns Hopkins School of Medicine, 1550 Orleans St, CRB II Room 309, Baltimore, MD 21287, USA  \n8 Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA  \n9 Department of Obstetrics and Gynecology, Johns Hopkins School of Medicine, Baltimore, MD, USA  \n10 Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins School of Medicine, Baltimore, MD, USA  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Comm","cbCaiiBoX2B6uYwT","https://ap.wps.com/l/cbCaiiBoX2B6uYwT","pdf",2892601,26,"English","# Abstract\n# Keywords\n# Introduction","[{\"question\":\"How do cancer vaccines relate to immune checkpoint inhibitors (ICIs)?\",\"answer\":\"Neoantigen vaccines can be used together with ICIs, which block proteins that suppress CD8 T cell cytotoxicity, and ICIs have shown strong performance in cancers with high mutational burden.\"}]","Molecular targets and strategies in the development of nucleic acid cancer vaccines - from shared to personalized antigens | PDF",1790022872,66,[139,143,147,151],{"page_no":8,"url":140,"width":141,"height":142},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd8f8a80da3ad0b3903bf73f6f426570.webp",983,1305,{"page_no":14,"url":144,"width":145,"height":146},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/260651b278df94b49bc74fc79832d935.webp",982,1304,{"page_no":81,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dbf69bb0a9c1607792601f78a7a22f1e.webp",981,1303,{"page_no":19,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/db8042507a3cc72ae8d2505afa6ff698.webp",980,1301]